The current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak poses a major challenge in the treatment decision-making of patients with cancer, who may be at higher risk of developing a severe and deadly SARS-CoV-2 infection compared with the general population. The health care emergency is forcing the reshaping of the daily assessment between risks and benefits expected from the administration of immune-suppressive and potentially toxic treatments. To guide our clinical decisions at the National Cancer Institute of Milan (Lombardy region, the epicenter of the outbreak in Italy), we formulated Coronavirus-adapted institutional recommendations for the systemic treatment of patients with gastrointestinal cancers. Here, we describe how our daily clinical practice has changed due to the pandemic outbreak, with the aim of providing useful suggestions for physicians that are facing the same challenges worldwide.

Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak : COVID-19-adapted Recommendations of the National Cancer Institute of Milan / F. Pietrantonio, F. Morano, M. Niger, S. Corallo, M. Antista, A. Raimondi, M. Prisciandaro, F. Pagani, N. Prinzi, F. Nichetti, G. Randon, M. Torchio, F. Corti, M. Ambrosini, F. Palermo, M. Palazzo, L. Biamonte, M. Platania, C. Sposito, M. Cosimelli, V. Mazzaferro, S. Pusceddu, C. Cremolini, F. de Braud, M. Di Bartolomeo. - In: CLINICAL COLORECTAL CANCER. - ISSN 1533-0028. - (2020 May 23). [Epub ahead of print] [10.1016/j.clcc.2020.05.004]

Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak : COVID-19-adapted Recommendations of the National Cancer Institute of Milan

Pietrantonio, Filippo;Prisciandaro, Michele;Randon, Giovanni;Corti, Francesca;Ambrosini, Margherita;Sposito, Carlo;Mazzaferro, Vincenzo;de Braud, Filippo;
2020-05-23

Abstract

The current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak poses a major challenge in the treatment decision-making of patients with cancer, who may be at higher risk of developing a severe and deadly SARS-CoV-2 infection compared with the general population. The health care emergency is forcing the reshaping of the daily assessment between risks and benefits expected from the administration of immune-suppressive and potentially toxic treatments. To guide our clinical decisions at the National Cancer Institute of Milan (Lombardy region, the epicenter of the outbreak in Italy), we formulated Coronavirus-adapted institutional recommendations for the systemic treatment of patients with gastrointestinal cancers. Here, we describe how our daily clinical practice has changed due to the pandemic outbreak, with the aim of providing useful suggestions for physicians that are facing the same challenges worldwide.
Colorectal cancer; Gastric cancer; Hepatobiliary cancer; Pancreatic cancer; SARS-CoV-2 pandemic
Settore MED/18 - Chirurgia Generale
Settore MED/06 - Oncologia Medica
Article (author)
File in questo prodotto:
File Dimensione Formato  
PIIS1533002820300773.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 309.24 kB
Formato Adobe PDF
309.24 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/760578
Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 12
social impact